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XCL1 is the ligand for XCR1, a chemokine receptor uniquely expressed on cross-
presenting dendritic cells (DC) in mouse and man. We are interested in establishing
therapeutic vaccines based on XCL1-mediated targeting of peptides or proteins into
these DC. Therefore, we have functionally analyzed various XCL1 domains in highly
relevant settings in vitro and in vivo. Murine XCL1 fused to ovalbumin (XCL1-OVA)
was compared to an N-terminal deletion variant lacking the first seven N-terminal
amino acids and to several C-terminal (deletion) variants. Binding studies with primary
XCR1+ DC revealed that the N-terminal region stabilizes the binding of XCL1 to its
receptor, as is known for other chemokines. Deviating from the established paradigm for
chemokines, the N-terminus does not contain critical elements for inducing chemotaxis.
On the contrary, this region appears to limit the chemotactic action of XCL1 at higher
concentrations. A participation of the XCL1 C-terminus in receptor binding or chemotaxis
could be excluded in a series of experiments. Binding studies with apoptotic and necrotic
XCR1-negative cells suggested a second function for XCL1: marking of stressed cells
for uptake into cross-presenting DC. In vivo studies using CD8+ T cell proliferation
and cytotoxicity as readouts confirmed the critical role of the N-terminus for antigen
targeting, and excluded any involvement of the C-terminus in the uptake, processing,
and presentation of the fused OVA antigen. Together, these studies provide basic data
on the function of the various XCL1 domains as well as relevant information on XCL1 as
an antigen carrier in therapeutic vaccines.
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INTRODUCTION
Murine XCL1 is a chemokine of 93 amino acids, and has been originally identified as lymphotactin
by Kelner et al. (1), while human XCL1 was found by us (2), and by Yoshida et al. (3). Mature
murine XCL1 exhibits a high degree of homology to human XCL1 (also 93 aa), with 61% identity
and 84% similarity, and both homologs have an identical structure [for alignment please refer to
Geyer et al. (4)]. The XCL1/XCR1 chemokine ligand-receptor pair exhibits some special structural
and functional features.
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XCL1 is secreted by activated NK cells, activated Th1-
polarized CD4+ T cells, and activated CD8+ T cells, and co-
secreted with IFN-γ, MIP-1α, MIP-1β, and RANTES and is thus
part of the Th1 immune defense (5, 6). XCR1 is the only receptor
for XCL1, and XCL1 is the only ligand of this receptor (7, 8).
Thus, this ligand/receptor pair is monogamous, a rare feature in
the world of around 50 chemokines.
The receptor XCR1 is exclusively expressed on a subset
of dendritic cells (DC), the “cross-presenting” DC (and not
elsewhere in the body), in the mouse, the rat, and the human
(4, 9–13). This narrow expression spectrum is another unusual
feature of the XCL1/XCR1 axis. XCR1+ DC, earlier designated
as CD8+ DC in the mouse, were demonstrated to be particularly
efficient in the uptake of cells stressed by (intracellular) infection
(14–16). Moreover, CD8+ DC have consistently been shown to
excel in antigen “cross-presentation,” in which exogenous antigen
is not presented in the context of MHC class II to CD4+ T cells,
but instead shunted into the MHC class I pathway of antigen
presentation to CD8+ T cells (17–19). Given the secretion profile
of XCL1, XCR1+ DC can be regarded as a DC population closely
cooperating with NK cells, Th1-polarized CD4+ T cells, and
CD8+ T cells in the surveillance of stressed/ transformed cells
for “danger” (16). The cross-presenting XCR1+ DC are now also
commonly referred to as cDC1.
In the past, we have employed this highly specific expression
of XCR1 to target antigens into cross-presenting DC in vivo. In
these experiments, ovalbumin (OVA), recombinantly fused to the
C-terminal portion of murine XCL1 (“XCL1-OVA”), was highly
efficient in inducing antigen-specific CD8+ T cell cytotoxicity,
when compared to untargeted OVA (20). These experiments
demonstrated that XCL1 can be employed as a carrier for
therapeutic vaccines intended to elicit potent antigen-specific T
cell cytotoxicity in vivo.
Because of this therapeutic potential, we are interested in the
structure-function relationship of various domains of XCL1. Like
classical chemokines, XCL1 has a free N-terminus of around
10 amino acids (aa), which is followed by a structured core
domain of around 60 aa containing a three-stranded antiparallel
beta-sheet and a C-terminal alpha-helix (classical “chemokine
fold”). The C-terminal portion of XCL1 of around 20 aa is,
typical for chemokines, again unstructured (21). The C-terminus
is highly conserved between mouse, rat, and human XCL1, and
of unknown function.
XCL1 is the only chemokine with one disulphide bridge,
while all other chemokines stabilize their tertiary structure by
two disulphide bridges. Kuloglu et al. (22) have demonstrated
in vitro that due to the lack of this second disulphide bridge,
XCL1 can assume at some more extreme conditions (45◦C, no
salt) an alternative conformation (which is exceptional in the
chemokine world), which could imply a second function. This
unusual feature raised the question whether the various domains
of XCL1 functionally differ from classical chemokines or whether
XCL1 has more than one function.
Abbreviations: DC, dendritic cells; OVA, ovalbumin; MFI, mean fluorescence
intensity.
To fully understand the usefulness of XCL1 as a vector
system for protein vaccines, we set out to systematically
test the contribution of XCL1-domains on receptor binding,
its chemotactic function, and on antigen processing and
presentation to CD8+ T cells in vivo. To this end, N-terminal
and C-terminal deletion variants of XCL1-OVA (which we have
previously used for antigen targeting in vivo [Hartung et al. (20),
see above] were generated. Further, we also replaced the entire
C-terminal domain of XCL1 with the C-terminal domain of viral
XCL1 (vXCL1), a rat cytomegalovirus-encoded XCL1 homolog,
which we have recently identified and characterized (4). vXCL1,
which can be assumed to interfere with the immune defense, has
a fully intact chemotactic activity on cross-presenting DC and
mainly differs in its C-terminal portion from its rat homolog.
We thus utilized the viral C-terminus in order to determine
whether this domain in some ways contributes to the function of
XCL1.
MATERIALS AND METHODS
Cloning, Expression, and Purification of
XCL1-OVA and Its Structural Variants
The DNA fragments coding for the various XCL1-OVA
constructs with a C-terminal Strep-tag (IBA, Germany) were
cloned into the drosophila expression vector pRmHa-3 (23)
by standard procedures. XCL1-OVA encoding plasmids were
electroporated together with the plasmid phshs.PURO into
drosophila Schneider SL-3 cells (24) using a Bio-Rad Gene
Pulser (450V and 500 mF). The phshs.PURO plasmid (kindly
provided by M. McKeown, Salk Institute) allows selection of
positive transfectants by puromycin. Clones from limiting
dilution cultures of transfected SL-3 cells were induced with
1mM CuSO4 and analyzed for high protein production using
either XCL1- or Strep-tag-specific ELISA. Positive clones
were expanded in Insect-XPRESS medium (Lonza) on a
shaker platform (100 rpm) in normal air at 27◦C. XCL1-OVA
proteins were purified from supernatants using Strep-Trap HP
columns from GE Healthcare according to the manufacturer’s
instructions. Protein concentration was determined by
measuring OD280 using a Nanodrop ND-1000 (Thermo
Scientific). LPS content in all protein samples was <0.5 EU/mg
protein.
Mice
C57BL/6 mice (8–12 week old) were used for experiments
and cell isolation, unless indicated otherwise. B6.XCR1-lacZ
(The Jackson Laboratory) are XCR1-deficient mice in which
the XCR1 gene has been replaced by the β-Gal reporter gene;
these mice were fully backcrossed (>10x) onto the C57BL/6
background. OT-I TCR-transgenic mice were crossed onto the
B6.PL background to allow identification of CD8+ T cells using
the CD90.1 marker. All mice were bred under specific pathogen-
free conditions in the animal facility of the Federal Institute for
Risk Assessment (Berlin, Germany). All animal experiments were
performed according to state guidelines and approved by the
local animal welfare committee.
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Cell Isolation
Splenocytes were obtained by mashing spleens through 70µm
cell sieves into PBS, followed by erythrocyte lysis with ACKBuffer
(155mM NH4Cl, 10mM KHCO3, 0.1mM EDTA).
Chemotaxis
To obtain sufficient DC for chemotaxis assays, C57BL/6 mice
were injected s.c. at 2 sites, each site with 1.5 × 106 B16 cells
secreting Flt3 ligand (25) for 9 days. DC were then enriched
by cutting spleens into small pieces followed by digestion with
Collagenase D (500µg/ml) and DNase I (20µg/ml, both Roche)
for 25min at 37◦C in RPMI 1640 containing 2% FCS (low
endotoxin, Biochrom); EDTA (10mM) was added for additional
5min and cells were filtered through a 70µm nylon sieve
(BD Falcon). DC were further enriched by centrifugation over
a 1.073 g/ml density gradient (NycoPrep, Axis-Shield). For
chemotaxis assays, 1 × 106 DC (purity ∼70%) were suspended
in 100 µl chemotaxis medium (RPMI 1,640, 1% BSA, 50mM
β-ME, 100 mg/ml penicillin/streptomycin) and placed into the
upper chamber of a 24-well Transwell system (6.5mm diameter,
5-µm pore polycarbonate membrane; Corning Costar). The
lower chamber was filled with chemotaxis medium to which
recombinant XCL1-OVA or the XCL1-variants were added. After
incubation in 5% CO2 for 2 h at 37
◦C, the number of migrated
DC was determined by counting cells in the lower chamber using
a flow cytometer. DC were identified by staining for XCR1, CD8,
CD11c, and MHC II after gating out cells expressing B220 and
CD3. The percentage of migrated cells was calculated by dividing
the number of cells in the lower chamber by the number of input
cells (number migrated cells/number input cells× 100).
In vivo Proliferation of OT-I T Cells
Recipient C57BL/6 mice were adoptively transferred with
splenocytes containing 1 × 106 OT-I (CD8+) resting T cells
(negative for CD25, CD69, and ICOS). For proliferation analysis,
OT-I cells were labeled with 5µM CFSE (Invitrogen) before
transfer and analyzed 48 h after immunization using the CFSE
dilution assay. Detection of OT–I T cells after adoptive transfer
was with mAb to CD8 and CD90.1 after gating out CD4+ T cells
and B220+ cells.
In vivo Cytotoxicity Assay
Animals were immunized with the indicated amounts of
either XCL1-OVA or the respective variants together with
3 µg of LPS (Sigma), which was mixed with the protein
variants before injection i.v.. 6 days later, 10 × 106 syngeneic
splenocytes were pulsed with SIINFEKL peptide (GenScript)
and labeled with 10µM CFSE (CFSEhigh) in vitro, while 10
× 106 splenocytes were left unpulsed and labeled with 1µM
CFSE (CFSElow). Both preparations were injected together i.v.
into immunized and control animals, and the CFSE signal
was determined by flow cytometry 18 h later. Specific lysis
was calculated using the following formula: specific lysis (%)
= 100–([CFSEhigh immunized/CFSElow immunized]/[CFSEhigh
control/CFSElow control])× 100.
Antibodies and Staining Reagents
Hybridomas producing mAb recognizing CD4 (clone YTS
191.1), CD8 (53–6.72), CD11c (N418), CD44 (IM7.8.1), CD45R
(B220 clone RA3-6B2), CD62L (MEL-14), Ly6G/C (RB6-8C5),
and MHC class II (M5/114.15.2) were obtained from ATCC,
CD90.1 (OX-7) from ECACC. Mab to CD69 (H1.2F3) was
from Biolegend, mAb PD-1 (J43) from eBioscience. Anti-CD3
(KT3) was generously provided byH. Savelkoul, anti-CD25 (2E4)
by E. Shevach. Generation of anti-XCR1 mAb MARX10 (13)
and anti-ICOS mAb [MIC-280 (26)] has been described before.
Mab MTAC-311 detects the C-terminal part of murine XCL1
(unpublished antibody and data). Generation of XCL1-StrepTag
is described in Hartung et al. (20). The non-agonistic mAb
MARX10 (mouse IgG2b, in the recombinant version IgG1) does
not block the binding of XCL1 to XCR1. OT–I T cells were
identified with mAbs to Vα2-TCR (B20.1, eBioscience) and Vβ5-
TCR (MR9-4, BD Biosciences). StrepMAB Immo conjugated to
Oyster 645 was from IBA Lifesciences.
Flow Cytometry
Antibodies were titrated for optimal signal-to-noise ratio. To
block unspecific binding to Fc-receptors, cells were pre-incubated
with 100µg/ml 2.4G2 mAb. Standard staining with mAb was in
PBS, 0.25% BSA, 0.1% NaN3 for 25min on ice. For exclusion
of dead cells 4′,6-diamidino-2-phenylindole (DAPI) was added
5min before measurement. Doublets and autofluorescent cells
were excluded from the analysis. Data were acquired on a LSRII
cytometer (BD Biosciences), and analyzed using FlowJo (Tree
Star Inc.). DC were defined as CD11c+ MHC-II+ Lin− cells.
Stressed Cells Assay
P3X63Ag8.653 myeloma cells (ATCC) were cultured at a density
of 2 × 106 cell/ml in complete RMPI1640 medium. Some cells
were exposed to heat shock (52◦C for 15min) and thereafter
cultured at a density of 2× 106 cells/ml in a 6-well plate overnight
at 37◦C and 5% CO2. Then, 0.5 × 10
6 cells were transferred into
24-well culture plate wells and 1 µg or 2 µg of wt XCL1-OVA
or one of its variants were added for the last hour of culture.
The cells were washed and stained with mAb StrepMAB Immo
conjugated to Oyster 645 (to detect bound XCL1-OVA) and
Annexin V-Cy5 (BD Pharmingen) in a binding buffer (10mM
Hepes, 140mM NaCl, 2,5mM CaCl2, 1% NaN3). After a further
washing step, cells taken up in binding buffer and were analyzed
by flow cytometry, DAPI was added just before analysis.
RESULTS
Generation of XCL1-OVA and the
Structural Variants Del-N7, Del-C7,
Del-C17, and vCterm
Various formats of XCL1 recombinantly fused to OVA were
generated in order to test for the impact of the various domains
(i) on the function of murine XCL1, (ii) on the ability of XCL1
to target the antigen OVA into XCR1+ DC in vivo, and (iii)
on the capacity of XCR1+ DC to process and cross-present the
attached antigen. The design, production, and in vivo targeting
capacity and specificity of XCL1-OVA, used here as the standard
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for comparison, has been described earlier (20). Del-N7 XCL1
is a variant lacking the first seven N-terminal amino acids (aa)
of XCL1, but is otherwise identical to XCL1-OVA (Figure 1A).
Del-C7 XCL1 lacks the C-terminal 7 aa, Del-C17 the C-terminal
17 aa of XCL1; in both deletion variants a glycine-serine linker
(GGGGS) was introduced C-terminally in order to (partially)
compensate for any size/positional effects (Figure 1B). vCterm
XCL1 is a variant in which the 17 C-terminal aa of murine XCL1
were replaced by the 20 C-terminal aa of a rat cytomegalovirus-
encoded XCL1 homolog (4). All constructs contained a
C-terminal Strep-tag to allow detection of the bound protein
variants to XCR1. The various constructs are represented
schematically in Figure 1A. For clarity, the C-terminal
sequences of the XCL1-variants are also shown (Figure 1B).
The constructs were used to express the protein in Schneider
cells.
The N-Terminus of XCL1 Is Critical for
Binding to XCR1
The binding of XCL1-OVA and its structural variants to its
receptor XCR1 was determined by incubating splenocytes with
carefully titrated concentrations of each reagent for 25min
on ice, followed by washing. The bound protein variants on
XCR1+ DC were then detected using an anti-Strep-tag mAb and
flow cytometry. Some of the results (incubation of the cells at
2.5, 0.625, 0.16, and 0.04µg/ml) are represented in histograms
in Figure 2A. Figure 2B summarizes experimental data points
obtained with all concentrations of the respective protein
variants. Small concentrations of XCL1-OVA (0.04µg/ml)
sufficed to achieve substantial binding, and saturation was
achieved at around 0.5µg/ml. The Del-C7 and Del-C17
structural variants showed a binding pattern comparable to
wildtype XCL1-OVA (Figures 2A,B). In contrast, the Del-N7
variant only bound at high concentrations of protein. At
2.5µg/ml, the binding efficiency of Del-N7 was comparable
to binding of XCL1-OVA at around 0.05µg/ml, and thus
was diminished around 50-fold. Incubation with vCterm XCL1
resulted in clearly stronger binding signals, when compared to
XCL1-OVA (Figures 2A,B).
To control for unspecific signals, the binding experiments
were repeated with cells from XCR1-deficient (XCR1−/−) mice
on the same C57BL/6 background. As can be seen from
Figure 2C, all variants exhibited a similar XCR1-unspecific
binding (only at this high concentration, data not shown), with
the exception of the Del-C17 variant.
These experiments determined that the first seven N-terminal
aa of XCL1 have a major influence on the binding of XCL1 to
its receptor, which can be partially compensated at high protein
concentrations by other structural elements of XCL1. At the same
time, the experiments excluded any significant contribution of
the C-terminal 17 aa to the binding of XCL1 to XCR1. Binding
studies with XCR1−/− dendritic cells further demonstrated that
all binding of XCL1 to the DC is mediated by XCR1; the
unspecific signals obtained at higher protein concentrations (2.5
µg) are apparently mediated by the C-terminal portion of XCL1
and are most likely of no major relevance in vivo.
Effects of the Structural Variants on
Chemotaxis
In order to determine the functional capacity of the XCL1-
OVA structural variants, DC were enriched from splenocytes and
tested at various concentrations of the variants for chemotaxis
in a transwell system. All of the cells which have migrated
into the lower chamber were quantitatively analyzed using
flow cytometry; therefore the intensity of the dot-plots truly
represents the number of migrated cells. The DC in the input cell
population were composed of around 70% of XCR1+ DC and
30% XCR1− DC (Figure 3A, leftmost dotplot in upper panel).
Virtually no migration into the lower chamber was observed
in the medium control, while both XCR1+ and XCR1− DC
migrated equally well to the chemokine CCL21, which was used
as a positive control (Figure 3A, upper panels). Essentially only
XCR1+ DC migrated in response to the various XCL1-OVA
constructs, with virtually no response of T cells, B cells or
other XCR1− cells (data not shown). The migration of XCR1+
DC to various concentrations of the XCL1-OVA standard (1
ng/ml−10,000 ng/ml) exhibited the bell-shaped curve typical for
chemokines, with maximal chemotactic activity at 100 ng/ml
(Figures 3A,B). A similar pattern was observed for Del-C7,
Del-C17, and also for vCterm (Figures 3A,B). With Del-N7,
barely any chemotaxis was observed up to 100 ng/ml and even
at 1,000 ng/ml the efficiency did not reach the maximum seen
with wt XCL1-OVA. Interestingly, by further increasing the
concentration of Del-N7 to 10,000 ng/ml in the lower chamber,
Del-N7 was chemotactically active above the levels seen with
optimal amounts (100 ng/ml) of wt XCL1-OVA (Figures 3A,B).
This was a consistent phenomenon throughout the experiments.
The results obtained in this functional experiment were
congruent with the previous binding studies. All XCL1-
OVA versions exhibiting good binding also induced effective
chemotaxis. Since the Del-C17 variant was similarly active
compared to XCL1-OVA, it can be concluded that the C-terminal
17 aa of XCL1 do not participate in the induction of chemotaxis
and thus must have other function(s). The positive functional
data obtained with Del-N7 XCL1 at very high concentrations
indicate that the core domain of XCL1 between aa 8 and 76
contains all necessary structural elements to induce chemotaxis.
The first 7 N-terminal aa apparently play a major role in the
stabilization of ligand binding to the receptor for induction of
chemotaxis. Interestingly, for unknown reason, this N-terminal
stretch of XCL1 seems also to limit the signaling at high ligand
concentrations.
Binding of XCL1-OVA and Its Variants
Del-N7, Del-C7, Del-C17, and vCterm to
Apoptotic and Necrotic Cells
As outlined in the introduction, XCL1 is an integral part of
the Th1-defense. Given the secretion of XCL1 by activated
NK cells, Th1-polarized CD4+ T cells, and by activated CD8+
T cells, we tested the hypothesis that secreted XCL1 could
“mark” stressed cells and thus facilitate their uptake by cross-
presenting DC. To test this hypothesis, we examined the
binding of wt XCL1-OVA and its structural variants to stressed
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FIGURE 1 | XCL1-OVA and its variants Del-N7, Del-C7, Del-C17, and vCterm. (A) Schematic representation of XCL1-OVA and its variants. Del-N7 lacks the first
seven amino acids (aa), in Del-C7 and Del-C17, the final 7 and 17 C-terminal aa were deleted, respectively. In vCterm, the 17 C-terminal aa were replaced by the 20
C-terminal aa of murid herpesvirus 8-encoded XCL1. (B) C-terminal aa sequences of XCL1 in the respective protein variants.
cells. To this end, P3X63Ag8.653 myeloma cells obtained from
standard culture (and thus without stress signals) were double-
stained with DAPI and Annexin V and arbitrarily subdivided
into populations designated as “live” (Annexin V− DAPI−),
“apoptotic” (Annexin V+ DAPIlow), “necrotic” (Annexin V+
DAPI+), and “dead” (Annexin V− DAPI+) (Figure 4A). While
live and dead cells did not exhibit a strong binding of the
various reagents, apoptotic and necrotic cells bound each
reagent to a substantial degree, with a rather uniform staining
pattern (Figure 4B, background staining with StrepMAB-Immo
in gray). When the P3X cells were subjected to thermal
stress (52◦C for 15min, followed by overnight culture), again
both necrotic and apoptotic cells bound the various reagents
in an uniform fashion (Figures 4C,D). To determine which
component(s) of the constructs was responsible for the observed
binding, additional experiments were performed. Live, apoptotic,
necrotic, and dead cells were reacted with XCL1 or with XCL1-
StrepTag and any bound reagent detected with a mAb directed
to murine XCL1 (Figure 4E). Only apoptotic and necrotic cells
gave the characteristic signal pattern, after incubation with
either XCL1 or XCL1-StrepTag. Since both reagents gave a
staining pattern similar to the other constructs (Figure 4B), any
significant binding of StrepTag or OVA to stressed cells could
be excluded. Together, these experiments determined that XCL1
was responsible for binding to stressed cells. Furthermore, it
could be concluded that the structured core region of XCL1 was
responsible for the binding to stressed cells, with no obvious
contribution of the free N-terminal or C-terminal regions.
Altogether, the data were compatible with the notion that XCL1
marks stressed cells.
Induction of CD8+ T Cell Proliferation and
Cytotoxic Capacity After in vivo Targeting
of Antigen With XCL1-OVA and Its Variants
Del-N7, Del-C7, Del-C17, and vCterm
In the next experiments we tested whether the various structural
elements of XCL1 influence targeting of antigen in vivo. To
this end, fluorescently labeled OT–I T cells were adoptively
transferred into syngeneic C57BL/6 mice. One day later, mice
were immunized i.v. with various amounts (0.1 µg, 0.3 µg,
1 µg) of wt XCL1-OVA, or alternatively with equal amounts
of its variants Del-N7, Del-C7, Del-C17, and vCterm without
adjuvant; PBS was used as negative control. After 48 h, spleens
were removed and the proliferation of the OT–I T cells
determined through dilution of the fluorescence signal using
flow cytometry. In two independent experiments, Del-C17
induced higher proliferation of the OT–I CD8+ T cells at
lower dosages, possibly reflecting its higher binding capacity
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FIGURE 2 | Binding of XCL1 and the structural variants Del-N7, Del-C7, Del-C17, and vCterm to XCR1 expressed on primary dendritic cells. Splenocytes were
incubated with carefully titrated (0.04, 0.08, 0.16, 0.315, 0.625, 1.25, and 2.5µg/ml) concentrations of all XCL1-OVA protein variants (all concentrations are given
based on the XCL1-component of the constructs) for 25min on ice, washed, and the bound protein was detected on Ly6G/C− CD3− B220− CD8+ CD11c+
MHC-II+ cells using an anti-Strep-tag mAb StrepMAB-Immo and flow cytometry (red histograms). Background staining, without pre-incubation, using
StrepMAB-Immo is shown in gray. (A) Signals obtained with XCL1-variants at 0.04, 0.16, 0.625, and 2.5µg/ml. (B) Graphical representation of the mean fluorescence
intensity (MFI) obtained in flow cytometry with all protein concentrations of the XCL1-OVA variants used. (C) Signals (shown for 0.625 and 2.5/µg/ml) obtained on
CD8+ DC lacking XCR1. Data are representative of 3 independent experiments.
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FIGURE 3 | Chemotaxis induced by XCL1-OVA and its variants Del-N7, Del-C7, Del-C17, and vCterm. (A) DC enriched from splenocytes by density gradient
centrifugation were placed in the upper chamber of a transwell system, the composition of input DC is shown in the leftmost dotplot in the upper pannel. Various
concentrations of wt XCL1-OVA and the structural variants were established in the lower chamber and migration of cells was allowed for 2 h. All concentrations are
given based on the XCL1-component of the constructs. Thereafter, all cells from the lower chambers were quantitatively analyzed by flow cytometry after staining for
XCR1 (mAb MARX10 binds to XCR1 independent of XCL1) and CD8 (mAb 53–6.2). Therefore, the number of events in the dot plots directly represent the number of
cells detected. The effect of the negative (medium) and the positive controls (CCL21) is shown in the upper pannels of dot plots. (B) Quantitave evaluation of migrated
XCR1+ DC expressed as percentage of input XCR1+ DC of the experiment shown in (A). One experiment representative of 2 independent experiments (each
independent experiment was done in duplicate on the same day and the data were combined (mean ± SEM).
(see Figure 2). vCterm was somewhat less effective, while Del-
C7 was comparable to the wt XCL1-OVA standard regarding
CD8+ T cell proliferation (Figures 5A,B). Del-N7 gave at 1 µg
a very subtle proliferation signal (Figure 5B). This experiment
demonstrated a comparably effective targeting of XCL1-OVA
in vivo into DC by all XCL1-OVA variants with comparable
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FIGURE 4 | Binding of XCL1-OVA and its variants Del-N7, Del-C7, Del-C17, and vCterm to apoptotic and necrotic cells. P3X63Ag8.653 cells were either (A,B,E)
cultured at standard conditions without stress, or (C,D) subjected to thermal stress (52◦C for 15min, followed by culture overnight). For the last hour of culture, 1 µg
of wt XCL1-OVA or one of its variants were added to the culture. For analysis, the cells were washed, and stained with DAPI and AnnexinV to subdivide the cells into
“live” (Annexin−DAPI−), “apoptotic” (AnnexinV+DAPIlow), “necrotic” (Annexin+DAPI+), and “dead” (Annexin−DAPI+) cells. (A) Gating and (B) staining of cells without
thermal stress, (C) gating and (D) staining of cells after thermal stress, using anti-StrepMAB-Immo for signal detection (red histograms); background staining with
StrepMAB-Immo without any preincubation is shown in gray histograms. (E) P3X63Ag8.653 cells were cultured under identical conditions, without thermal stress. For
the last hour of culture, 1 µg of wt XCL1 or XCL1-StrepTag were added to the culture. Washing of cells and gating with DAPI and AnnexinV was as described above.
Signal was detected with mAb MTAC-311 specific for murine XCL1 (red histograms), background signals with MTAC-311, without any preincubation, are shown in
gray. Concentrations of XLC1-variants are based on the XCL1-component of the respective construct.
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FIGURE 5 | Induction of CD8+ T cell proliferation after in vivo targeting of antigen using XCL1-OVA and its variants Del-N7, Del-C7, Del-C17, and vCterm.
Fluorescently labeled OT-I T cells (1 × 106) were adoptively transferred into syngeneic C57BL/6 mice. One day later the animals were immunized with the indicated
amounts (based on the content of OVA) of wt XCL1-OVA and its structural variants (w/o adjuvant). Two days after immunization, the spleens were removed and the
percentage of proliferated OT–I T cells was determined using the CSFE dilution assay in flow cytometry. (A) Exemplary histograms of the fluorescence signal obtained
with 0.3 µg of each protein reagent. (B) Percentage of proliferated OT-I T cells after immunization with 0.1, 0.3, and 1 µg of each protein reagent. Combined data
from 2 independent experiments are shown (mean ± SEM).
binding capacity in vitro. This observation excluded a major
effect of the C-terminal portion of XCL1 on OVA processing and
presentation.
Induction of Cytotoxic Capacity After
in vivo Targeting of Antigen With
XCL1-OVA and Its Variants Del-N7, Del-C7,
Del-C17, and vCterm
To further test the in vivo functional capacity of T cells induced
by the various formats of targeted antigen, C57BL/6 mice were
immunized i.v. with titrated amounts of wt XCL1-OVA and its
variants, which were injected together with 3 µg LPS. On day 6,
an in vivo cytotoxicity assay was performed. As can be seen from
Figure 6, Del-C7, Del-C17, and vCterm were similarly effective
in inducing cytotoxicity as XCL1-OVA. The Del-N7 variant, at
3.3 µg, also induced modest cytotoxic activity. The cytotoxicity
results were thus congruent with the proliferation data of OT–
I T cells obtained earlier and excluded a major effect of the
C-terminal portion of XCL1 on the induction of cytotoxicity
in vivo.
DISCUSSION
Structures of many chemokines have been solved by NMR and
X-ray crystallography. These studies revealed that despite low
sequence homology, chemokines adopt a remarkably conserved
tertiary structure consisting of a disordered N-terminus of 6–10
aa, a structured core region (chemokine fold), and a disordered
C-terminus of variable length (27, 28). From a great number
of structure-function studies a general concept evolved which
assumes an initial specific binding of the chemokine fold-domain
to the N-terminus of the receptor. In a second step, this initial
interaction is stabilized by a subsequent integration of the N-
terminal disordered domain of the ligand into the orthosteric
pocket of the receptor. Additional studies suggested that this N-
terminal domain of the chemokine ligand has signaling capacity.
For example, an N-terminal deletion variant of MCP-19−76
bound to its receptor with similar strength compared to the wild-
type version MCP-11−76, but had lost all chemotactic activity
(29). Based on many experiments of this type, the disordered
N-terminal region of chemokines is generally regarded as a key
signaling domain (27, 28).
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FIGURE 6 | Induction of cytotoxic capacity after in vivo targeting of antigen with XCL1-OVA and its variants Del-N7, Del-C7, Del-C17, and vCterm. C57BL/6 mice
were immunized with the indicated amounts of wt XCL1-OVA and its variants (based on the content of OVA) together with 3 µg LPS on day 0. On day 6, the animals
were injected with CFSE-labeled target cells to quantitate the induced cytotoxicity in vivo (for details, see Materials and Methods). (A) Exemplary flow cytometry
histograms of the data obtained with 0.3 µg of each reagent. (B) Percentage of specific lysis obtained with 0.3, 1 and 3.3 µg of each reagent (mean ± SEM).
In our work, the N-terminal deletion variant Del-N7
(XCL18−93) reduced the binding of murine XCL1 to its receptor
XCR1 approximately 50-fold. This reduction in binding was
accompanied by a similar reduction in chemotaxis. The capacity
of XCL1 to bind to its receptor was thus directly correlated to its
chemotactic action. These data are compatible with a stabilization
of the ligand-receptor interaction and thus with the general
concept. However, we also made the surprising observation
that at very high concentrations (approximately 100-fold of
the presumed physiological concentration), this N-terminal
deletion variant still exhibited fully preserved chemotactic
action. Thus, with murine XCL1 there is no indication of
an important signaling element in the N-terminal disordered
domain which would be required for chemotaxis, as suggested
by the general concept. Interestingly, at these supra-physiological
concentrations (10,000 ng/ml) the N-terminal deletion variant
consistently induced higher chemotaxis, when compared to
the wild-type XCL1 at its optimal concentration (100 ng/ml).
This observation indicates that the chemokine fold of XCL1
contains all necessary structures to induce chemotaxis. Finally,
wild-type XCL1 at the same supra-physiological concentrations
(10,000 ng/ml), exhibited largely reduced chemotaxis compared
to its optimum at 100 ng/ml (as is typical for chemokines). This
observation suggest that the disordered N-terminal region of
XCL1 in some ways limits the functional activity of XCL1 at high
concentrations.
When we analyzed the functional contribution of the C-
terminal portion of murine XCL1, the deletion variants Del-
C7 (XCL11−86) and Del-C17 (XCL11−76) did not show any
functional effects on receptor binding or chemotaxis. Thus,
we can exclude a major contribution of this region to the
chemotactic function of murine XCL1. This conclusion clearly
differs from the findings of a study utilizing human XCL11−72
(30), where a complete loss of calcium activity was observed.
However, this particular C-terminal deletion variant was 4 aa
shorter than Del-C17 (XCL11−76) which was used in the present
study. Our results are fully compatible with data on a series of
C-terminally truncated variants of human XLC1 (1–68, 1–72,
1–78, and 1–85), which all elicited normal calcium signals in
XCR1-transfected HEK-293 cells (31).
Regarding the structure-function relationship of murine
XCL1, our data can be summarized as follows. The core
domain of XCL1 contains all necessary structural elements
to specifically bind to XCR1 and to elicit chemotaxis. This
observation differs from the general concept for chemokines,
which assumes a critical signal contribution of the N-terminal
domain for chemotaxis (27, 28). The first 7 aa of the N-terminal
domain stabilize the binding of XCL1 to its receptor and thus
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certainly optimize chemotaxis. At the same time, and apparently
paradoxically, the first 7 aa appear to limit the chemotactic
effect of supra-physiological concentrations of murine XCL1,
suggesting some type of negative regulatory role of the N-
terminus at high XCL1 concentrations. A contribution of the
disordered C-terminus of XCL1 to chemotaxis can clearly be
ruled out.
These conclusions were reached with binding and chemotaxis
assays using primary cells expressing the native XCR1 receptor.
This is in contrast to the very few studies on the structure-
function relationship of XCL1, which were conducted with
XCR1-transfectants and mainly based on calcium mobilization
studies.
Since XCL1 is secreted by activated NK cells, we pursued the
hypothesis that in addition to its chemotactic function, XCL1
could “decorate” stressed cells recognized by NK cells. In such
a scenario bound XCL1 could mark these stressed cells for
phagocytosis by DC specialized for uptake of such cells (16).
Using a murine myeloma line as an in vitro model system
and also employing heat-shock experiments, we consistently
observed binding of XCL1 to cells characterized as “necrotic”
or “apoptotic,” based on the use of Annexin V and DAPI.
This binding was clearly mediated by the chemokine fold of
XCL1, with no apparent contribution of the disordered N-
terminal or C-terminal regions. It is unclear at present, to
which structural elements present on apoptotic and necrotic
cells XCL1 binds. Therefore, it remains to be determined
whether this binding is specific or mediated by structural
elements common to many chemokines, e.g., domains capable
to mediate binding to glycosaminoglycans (present in the
core domain of chemokines, also with XCL1). Preliminary
studies with primary cells gave similar results as with the
myeloma line, but turned out to be less reproducible, and
therefore more work is needed to reach firm conclusions
here. In particular, in vivo work will be required to generate
essential data in order to support or reject the “decoration”
hypothesis.
We are interested to use XCL1 as a carrier to transport
proteins or peptides into cross-presenting DC. Therefore, all
experiments were performed with XCL1 variants which were C-
terminally fused to full-length OVA. We wanted to determine
whether the various domains of XCL1 exert any influence
on the targeting of the model protein to XCR1+ DC in
vivo. As independent and very sensitive readouts for CD8+
T cell activation we used both induction of proliferation
(response by adoptively transferred OT-I T cells) as well as
induction of cytotoxic activity (by endogenous CD8+ T cells).
Since CD8+ T cells in vivo become activated through cross-
presentation of the soluble antigen OVA (17–19), we assume
that these readouts measure cross-presentation of OVA-derived
peptide SIINFEKL by XCR1+ DC in vivo. They thus reflect
the combined effects of antigen uptake, efficiency of antigen
processing, and antigen presentation on the cell surface of the
DC. Previous experiments which demonstrated that targeting
of OVA using either XCL1 or an antibody directed to murine
XCR1 drastically reduces the amount of antigen necessary
to elicit CD8+ T cell responses in vivo (20) support this
assumption.
Several conclusions can be reached from our experiments
regarding the use of XCL1 as antigen carrier. First, an intact
N-terminus is required to efficiently target any peptide/protein
cargo to XCR1+ DC. Second, attachment of a relatively large
protein cargo of around 40 kDa to the C-terminus does
not sterically inhibit binding of XCL1 to its receptor. Third,
attachment of protein cargo does not influence chemotaxis of
XCR1+ DC (chemotaxis was identical when compared with
native XCL1 without OVA, data not shown). Since a chemotactic
signal usually induces internalization of the chemokine receptor
(27, 28), we assume that fusion of protein cargo to XCL1
does not influence the uptake of the protein into XCR1+ DC.
Fourth, the disordered C-terminus can be eliminated from
XCL1, if necessary, when using protein cargo without any
obvious deficits in antigen uptake and presentation. The last
conclusion is supported by exchanging the natural C-terminus
of XCL1 with the C-terminal domain of murid herpesvirus 8-
encoded XCL1, which also did not show any changes in antigen
presentation.
The conclusions on the capacity of XCL1 as an antigen
carrier were reached with the model antigen OVA. Since this
particular antigen is ideal in that it is highly soluble and
shows little interaction with other proteins, there may be
some limitations to the conclusions reached. Other proteins
prone to binding to other structures in the body may not
as efficiently be transported to XCR1+ DC as OVA. Other
cargo proteins may also interact with XCL1 in an intra- or
intermolecular fashion. In spite of these potential limitations,
our data clearly demonstrate the usefulness of XCL1 as a
carrier to directly target large proteins or peptides to XCR1+
cross-presenting DC. Such an antigen carrier system appears
attractive for induction of antigen-specific cytotoxicity in anti-
tumor therapeutic vaccines.
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